Reported 2 days ago
Eli Lilly and Pfizer have been prominent players in the pharmaceutical industry, especially during the COVID-19 pandemic, but both companies have faced recent stock declines—Lilly by about 25% and Pfizer by roughly 20%. This drop is largely attributed to disappointing third-quarter earnings for Lilly and Pfizer's recent setbacks, including the withdrawal of a therapy due to safety concerns. Despite these challenges, analysts suggest that long-term investors should not rush to sell their shares, as both companies are expected to navigate their current hurdles and continue to have growth opportunities.
Source: YAHOO